Ole S Søgaard Selected Research

camostat

1/2022	A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste.
10/2021	Determination of camostat and its metabolites in human plasma - Preservation of samples and quantification by a validated UHPLC-MS/MS method.
5/2021	Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.
3/2021	Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
2/2021	Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety.
8/2020	Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ole S Søgaard Research Topics

Disease

14	Infections 05/2021 - 08/2011
10	COVID-19 01/2022 - 08/2020
7	HIV Infections (HIV Infection) 01/2020 - 01/2012
4	Viremia 01/2018 - 07/2015
3	Inflammation (Inflammations) 01/2021 - 08/2011
3	Neoplasms (Cancer) 07/2019 - 01/2014
2	Papillomavirus Infections 01/2018 - 12/2014
2	Bacteremia 01/2015 - 05/2012
2	Acquired Immunodeficiency Syndrome (AIDS) 06/2010 - 09/2009
1	Ageusia (Hypogeusia) 01/2022
1	Fatigue 01/2022
1	Anosmia 01/2022
1	Prostatic Neoplasms (Prostate Cancer) 10/2021
1	Human Influenza (Influenza) 02/2021
1	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 01/2021
1	Thrombosis (Thrombus) 01/2021
1	Thrombocytopenia (Thrombopenia) 01/2021
1	Stomach Neoplasms (Stomach Cancer) 12/2020
1	Pancreatitis 08/2020
1	Communicable Diseases (Infectious Diseases) 07/2019
1	Shock 01/2017
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2015
1	Sepsis (Septicemia) 01/2015
1	Injection Site Reaction 04/2014
1	Chronic Disease (Chronic Diseases) 04/2013
1	Coinfection 08/2011
1	Meningococcal Meningitis 08/2011
1	Pneumonia (Pneumonitis) 09/2009
1	Ventilator-Associated Pneumonia 01/2006

Drug/Important Bio-Agent (IBA)

6	camostatIBA 01/2022 - 08/2020
6	Antiviral Agents (Antivirals)IBA 01/2022 - 11/2012
5	VaccinesIBA 06/2021 - 06/2010
4	AntibodiesIBA 01/2021 - 05/2012
3	Pharmaceutical PreparationsIBA 01/2022 - 02/2021
2	CytokinesIBA 01/2022 - 08/2011
2	Protease Inhibitors (Protease Inhibitor)IBA 03/2021 - 08/2020
2	Peptide Hydrolases (Proteases)FDA Link 03/2021 - 08/2020
2	Messenger RNA (mRNA)IBA 01/2021 - 04/2015
2	18 16 11 Types 6 Human Papillomavirus Recombinant Vaccine Quadrivalent (Gardasil)FDA Link 01/2018 - 04/2014
2	18 L1 type 16 human papillomavirus vaccine (Cervarix)IBA 01/2018 - 04/2014
2	Papillomavirus Vaccines (HPV Vaccines)IBA 01/2018 - 12/2014
2	romidepsin (FK228)FDA Link 01/2017 - 07/2015
2	Tenofovir (Viread)FDA Link 11/2012 - 08/2011
1	Nucleic AcidsIBA 01/2022
1	InterferonsIBA 01/2022
1	Serine Proteases (Serine Protease)IBA 05/2021
1	Proteins (Proteins, Gene)FDA Link 02/2021
1	Serine Proteinase Inhibitors (Serine Protease Inhibitors)IBA 02/2021
1	Neutralizing AntibodiesIBA 02/2021
1	Thrombin FDA Link 01/2021
1	mRNA VaccinesIBA 01/2021
1	COVID-19 VaccinesIBA 01/2021
1	Ad26COVS1IBA 01/2021
1	Biological ProductsIBA 12/2020
1	Toll-Like Receptor 9IBA 06/2017
1	Fc Receptors (Fc Receptor)IBA 01/2017
1	RNA (Ribonucleic Acid)IBA 01/2017
1	Histone Deacetylase InhibitorsIBA 07/2015
1	Biomarkers (Surrogate Marker)IBA 04/2015
1	Anti-Infective Agents (Microbicides)IBA 11/2012
1	Indicators and Reagents (Reagents)IBA 01/2012
1	InterleukinsIBA 08/2011
1	Reverse Transcriptase InhibitorsIBA 08/2011
1	Toll-Like Receptors (Toll-Like Receptor)IBA 08/2011
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2011
1	Interleukin-12 (IL 12)IBA 08/2011
1	LigandsIBA 08/2011
1	NucleosidesIBA 08/2011
1	ProMune (CpG 7909)IBA 06/2010
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2006

Therapy/Procedure

7	Therapeutics 12/2020 - 07/2015
5	Highly Active Antiretroviral Therapy (HAART) 01/2020 - 09/2009
1	Oral Administration 01/2022
1	Transplantation 01/2020
1	Immunotherapy 07/2019
1	Aftercare (After-Treatment) 01/2018
1	Secondary Prevention 01/2017
1	Art Therapy 07/2015
1	Renal Replacement Therapy (Therapies, Renal Replacement) 01/2015
1	Peritoneal Dialysis 01/2015
1	Renal Dialysis (Hemodialysis) 01/2015